Zypadhera(TM) Receives European Approval for Maintenance Treatment of Schizophrenia (y 2)

McDonnell D., Andersen S., Detke H., Watson S. 160-week interim results from an open-label extension trial of olanzapine long-acting injection. Data presented at the Schizophrenia International Research Society, June 21-25, 2008, Venice, Italy.

HGJW:

Mamo D., Kapur S., Keshavan M, Laruelle M, Taylor C.C, Kothare P.A., Barsoum P., McDonnell D. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology, 2008; 33(2):298-304.

LOBE

Kurtz D., Bergstrom R., McDonnell D., Mitchell M. Pharmacokinetics of multiple doses of olanzapine long-acting injection, an intramuscular depot formulation of olanzapine, in stabilized patients with schizophrenia. Data presented at the Society for Biological Psychiatry, May 1-3, 2008, Washington, DC.

LOBS, LOBO : data on file

HGLQ

Detke H., McDonnell D., Andersen S., Watson S. Olanzapine long-acting injection in patients with schizophrenia at risk of relapse: 12-week switching data. Data presented at the European College of Neuropsychopharmacology, August 30-September 3, 2008, Barcelona, Spain.

v. McDonnell D., Sorsaburu S., Brunner E., Detke H., Andersen S., Bergstrom R., Mitchell M., Ogle K., Watson S., Corya S. Post-injection delirium/sedation observed with olanzapine long-acting injection: review of the first 25 events. Data presented at the European College of Neuropsychopharmacology, August 30-September 3, 2008, Barcelona, Spain.

vi. Falkai P., Wobrock T., Lieberman J., Glenthoj B.,Gattaz W.F., Moller H.J & Wfsbp Task Force On Treatment Guidelines For Schizophrenia. The World Journal of Biological Psychiatry, 2006; 7(1): 5/40

vii. Kane J.M et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology, Volume 8, Number 1, 1 February 1998, pp. 55-66(12). p. 58.

viii. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition, 2000, pp. 298.

(Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

Janell Smith, Eli Lilly and Company, U.S., +1-317-277-9603, +1-317-358-5396 mobile, Smith_Janell@lilly.com. Photo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO